Table 2.

Adverse Events

Event	Patients [n (%)] (N = 58)
Any adverse event reported	55 (94.8)
Any serious adverse event reported	4 (6.9)
Interruption of treatment due to an adverse event	6 (10.3)
Discontinuation of treatment due to an adverse event	2 (3.4)
Adverse events by severity
Mild	22 (37.9)
Moderate	29 (50.0)
Severe	4 (6.9)
Common adverse events (incidence ≥10%)
Cough	29 (50.0)
Nasal congestion	12 (20.7)
Infective pulmonary exacerbation	12 (20.7)
Headache	12 (20.7)
Increased sputum	8 (13.8)
Upper abdominal pain	8 (13.8)
Elevated alanine aminotransferase levels	7 (12.1)
Abdominal pain	6 (10.3)
Nausea	6 (10.3)
Vomiting	6 (10.3)
Fatigue	6 (10.3)
Pyrexia	6 (10.3)
Serious adverse events
Infective pulmonary exacerbation	2 (3.4)
Ileus	1 (1.7)
Elevated liver transaminase levels	1 (1.7)
Respiratory events	4 (6.9)
Dyspnea	1 (1.7)
Respiration abnormal	1 (1.7)
Wheezing	2 (3.4)